ACTINIUM PHARMACEUTICALS INC (ATNM)
US00507W2061 - Common Stock
Taking everything into account, ATNM scores 2 out of 10 in our fundamental rating. ATNM was compared to 564 industry peers in the Biotechnology industry. The financial health of ATNM is average, but there are quite some concerns on its profitability. ATNM is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ATNM had negative earnings in the past year.
ATNM had a negative operating cash flow in the past year.
ATNM had negative earnings in each of the past 5 years.
In the past 5 years ATNM reported 4 times negative operating cash flow.
1.2 Ratios
ATNM has a Return On Assets (-49.83%) which is comparable to the rest of the industry.
With a Return On Equity value of -107.08%, ATNM perfoms like the industry average, outperforming 43.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.83% | ||
| ROE | -107.08% | ||
| ROIC | N/A |
ROA(3y)-39.89%
ROA(5y)-68.16%
ROE(3y)-72.51%
ROE(5y)-128.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ATNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ATNM has been increased compared to 1 year ago.
The number of shares outstanding for ATNM has been increased compared to 5 years ago.
The debt/assets ratio for ATNM is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.44, we must say that ATNM is in the distress zone and has some risk of bankruptcy.
ATNM has a worse Altman-Z score (-6.44) than 67.33% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ATNM is not too dependend on debt financing.
The Debt to Equity ratio of ATNM (0.00) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.44 |
ROIC/WACCN/A
WACC10.61%
2.3 Liquidity
A Current Ratio of 10.25 indicates that ATNM has no problem at all paying its short term obligations.
The Current ratio of ATNM (10.25) is better than 81.87% of its industry peers.
ATNM has a Quick Ratio of 10.25. This indicates that ATNM is financially healthy and has no problem in meeting its short term obligations.
ATNM's Quick ratio of 10.25 is amongst the best of the industry. ATNM outperforms 82.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.25 | ||
| Quick Ratio | 10.25 |
3. Growth
3.1 Past
ATNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.46%, which is quite impressive.
Looking at the last year, ATNM shows a very negative growth in Revenue. The Revenue has decreased by -92.14% in the last year.
EPS 1Y (TTM)27.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.49%
Revenue 1Y (TTM)-92.14%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ATNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.14% yearly.
Based on estimates for the next years, ATNM will show a very strong growth in Revenue. The Revenue will grow by 203.41% on average per year.
EPS Next Y26.16%
EPS Next 2Y27.11%
EPS Next 3Y10.64%
EPS Next 5Y8.14%
Revenue Next Year26.1%
Revenue Next 2Y1462.04%
Revenue Next 3Y689.91%
Revenue Next 5Y203.41%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ATNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.11%
EPS Next 3Y10.64%
5. Dividend
5.1 Amount
ATNM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACTINIUM PHARMACEUTICALS INC
NYSEARCA:ATNM (1/3/2025, 8:20:58 PM)
After market: 1.37 -0.07 (-4.86%)1.44
+0.18 (+14.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners28.13%
Inst Owner Change14.58%
Ins Owners2.04%
Ins Owner Change0%
Market Cap44.93M
Analysts81.82
Price Target5.1 (254.17%)
Short Float %5.86%
Short Ratio5.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.03%
Min EPS beat(2)-7.96%
Max EPS beat(2)8.01%
EPS beat(4)3
Avg EPS beat(4)19.97%
Min EPS beat(4)-7.96%
Max EPS beat(4)41.55%
EPS beat(8)5
Avg EPS beat(8)6.59%
EPS beat(12)6
Avg EPS beat(12)-10.07%
EPS beat(16)9
Avg EPS beat(16)-6.5%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 554.67 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.18 | ||
| P/tB | 1.18 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.4
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0
BVpS1.22
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.83% | ||
| ROE | -107.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-39.89%
ROA(5y)-68.16%
ROE(3y)-72.51%
ROE(5y)-128.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.36% | ||
| Cap/Sales | 13.58% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.25 | ||
| Quick Ratio | 10.25 | ||
| Altman-Z | -6.44 |
F-Score5
WACC10.61%
ROIC/WACCN/A
Cap/Depr(3y)32.37%
Cap/Depr(5y)33.78%
Cap/Sales(3y)78.68%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.49%
EPS Next Y26.16%
EPS Next 2Y27.11%
EPS Next 3Y10.64%
EPS Next 5Y8.14%
Revenue 1Y (TTM)-92.14%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year26.1%
Revenue Next 2Y1462.04%
Revenue Next 3Y689.91%
Revenue Next 5Y203.41%
EBIT growth 1Y14.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.21%
EBIT Next 3Y2.27%
EBIT Next 5Y-3.84%
FCF growth 1Y-415.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-406.16%
OCF growth 3YN/A
OCF growth 5YN/A